Relationship between gender and perioperative clinical features in lung cancer patients who underwent VATS lobectomy

Table 1 Comparison of baseline data between males and females

Characteristic	male(n = 174)	female(n = 164)	statistics	P
age	59.13 ± 9.50[28–83]	56.19 ± 10.00[26–77]	2.775	0.006
BSA	1.75 ± 0.15[1.33–2.21]	1.57 ± 0.11[1.3–1.87]	12.104	<0.001
BMI	23.84 ± 2.95[16.02–37.80.]	23.60 ± 3.20[15.60–32.27]	0.712	0.477
smoking history	120(69.0)	10(6.1)	140.98	<0.001
chronic alcohol consumption	97(55.8)	4(2.4)	114.51	<0.001
comorbid diseases
hypertension	44(25.3)	26(15.9)	4.576	0.032
diabetes	17(9.8)	10(6.1)	1.549	0.213
lung disease	16(9.2)	5(3.0)	5.474	0.19
heart disease	6(3.4)	2(1.2)	1.815	0.178
tumor history	11(6.3)	8(4.9)	0.332	0.565
lung function
FEVI	2.59 ± 0.67[0.74–5.39]	2.02 ± 0.49[0.73–3.34]	8.995	<0.001
FEV1 Pre / Ref	89.27 ± 18.86[31.3–183.4]	95.03 ± 18.03[41.7–160]	-2.867	0.004
FEV1/FVC%	84.69 ± 9.47[58.76–99.99]	87.89 ± 8.58[58.35–99.76]	-3.248	0.001
lesion diameter	2.78 ± 1.54[0.9–7.6]	2.16 ± 1.10[0.6–7.3]	4.312	<0.001
lesion composition			25.979	<0.001
ground-glass	60(34.5)	102(62.2)
solid	114(65.5)	62(37.8)
surgical method			3.468	0.486
RUL	67(38.5)	51(31.1)
RML	10(5.7)	16(9.8)
RLL	33(19.0)	34(20.7)
LUL	43(24.7)	40(24.4)
LLL	21(12.1)	23(14.0)
tumor types			25.291	<0.001
AD	132(75.9)	156(95.1)
SCC	38(21.8)	8(4.9)
Other	4(2.3)	0
T stage			23.026	<0.001
0–1	77(44.3)	115(70.1)
≥ 2	97(55.7)	49(29.9)
N stage			3.32	0.068
0	148(85.1)	150(91.5)
1,2	26(14.9)	14(8.5)
clinical stage			15.992	<0.001
MIS-I	112(64.3)	137(83.6)
II-III	62(35.7)	27(16.4)

BSA, body surface area. BMI, body mass index. RUL, right upper lobe. RML, right middle lobe. RLL, right lower lobe. LUL, left upper lobe. LLL left lower lobe. AD, adenocarcinoma
classification as T stage and N stage according to the TNM system and clinical staging

ISSN: 1749-8090